Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
RESEARCH TOOLSreports
Aurinia Pharmaceuticals (AUPH) Stock Price & Analysis
1,895 Followers
AUPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.71 - $12.43
Previous Close$5.15
Volume26.66K
Average Volume (3M)2.12M
Market Cap
$733.69M
Enterprise Value$483.67M
Total Cash (Recent Filing)$350.49M
Total Debt (Recent Filing)$97.61M
Price to Earnings (P/E)-11.8
Beta1.18
Next Earnings
Aug 01, 2024EPS Estimate
<$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding144,617,762
10 Day Avg. Volume1,512,502
30 Day Avg. Volume2,115,986
Standard Deviation0.31
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.99
Price to Sales (P/S)16.52
Price to Cash Flow (P/CF)12.90
P/FCF Ratio11.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit3.00
Enterprise Value/Ebitda-6.26
Forecast
1Y Price Target
$10.83Price Target Upside111.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aurinia Pharmaceuticals News
PremiumCompany Announcements
Aurinia Highlights LUPKYNIS Success in Lupus Treatment
PremiumCompany Announcements
Aurinia Pharmaceuticals to Engage at RBC Healthcare Conference
PremiumCompany Announcements
Aurinia Pharmaceuticals Sees Robust Growth in 2024PremiumCompany Announcements
Aurinia Pharmaceuticals Files SEC Report
PremiumCompany Announcements
Aurinia Advances Lupus Nephritis Education and AdvocacyBulls Say, Bears Say
Bulls Say
Financial HealthThe company is expected to generate free cash flow ahead of prior expectations, which could be an attractive milestone for investors.
Market Approval And SentimentLUPKYNIS has been approved in the U.S. and Europe, with high projections for peak sales and royalties.
Product DemandLupkynis sales exceeded estimates, suggesting a favorable launch trend with strong momentum.
Bears Say
Corporate StrategyShares have dropped to a 52-week low following the conclusion of the strategic review without a transaction.
Drug Efficacy And SafetyConcerns remain regarding long-term treatment persistency rates for LUPKYNIS.
Financial PerformanceKey risks include potential revenue growth below expectations, safety issues, and patent challenges that could affect the market.
---
Ownership Overview
60.24% Insiders
4.05% Mutual Funds
6.10% Other Institutional Investors
29.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $4.71 and its highest was $12.43 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Currently, no data Available
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 84 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on May 02, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.137 by $0.067.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is <$0.01.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 143,019,360 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.137. Following the earnings report the stock price went down -0.577%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
---
Aurinia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.83 (111.11% Upside)
$10.83 (111.11% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.97%
12-Months-Change
Fundamentals
Return on Equity
-16.69%
Trailing 12-Months
Asset Growth
14.36%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
---
AUPH Earnings Call
Q1 2024
0:00 / 0:00
---
AUPH Revenue Breakdown
90.33% Product revenue, net
9.67% License and contract revenue
---
AUPH Stock 12 Month Forecast
Average Price Target
$10.83
▲(111.11% Upside)
Technical Analysis
Best Analysts Covering AUPH
1 Year
1 Year Success Rate
13/30 ratings generated profit
1 Year Average Return
+8.74%
assigned a buy rating 8 days ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 43.33% of your transactions generating a profit, with an average return of +8.74% per trade.
---